|
1
|
Ye X, Lu D, Chen X, Li S, Chen Y and Deng
L: A multicenter, randomized, double-blind, placebo-controlled
trial of shuangbai san for treating primary liver cancer patients
with cancer pain. J Pain Symptom Manage. Feb 26–2016.(Epub ahead of
print). View Article : Google Scholar
|
|
2
|
Zeng K, Dong HJ, Chen HY, Chen Z, Li B and
Zhou QH: Wrist-ankle acupuncture for pain after transcatheter
arterial chemoembolization in patients with liver cancer: a
randomized controlled trial. Am J Chin Med. 42:289–302. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu X, Li Q, Chang R, Yang D, Song Z, Guo
Q and Huang C: Curcumin alleviates neuropathic pain by inhibiting
p300/CBP histone acetyltransferase activity-regulated expression of
BDNF and cox-2 in a rat model. PLoS One. 9:e913032014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang C, Tan W, Huang X, Fu T, Lin J, Bu J,
Wei G and Du Y: Curative effect of Dingqi analgesic patch on cancer
pain: a single-blind randomized controlled trail. J Tradit Chin
Med. 33:176–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou B, Wang J, Yan Z, Shi P and Kan Z:
Liver cancer: effects, safety, and cost-effectiveness of
controlled-release oxycodone for pain control after TACE.
Radiology. 262:1014–1021. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang YP and Ru QJ: Cases of postoperative
pain of liver cancer after transcatheter arterial
chemoembolization. Zhongguo Zhen Jiu. 33:7782013.(In Chinese).
PubMed/NCBI
|
|
7
|
Nabal M, Librada S, Redondo MJ, Pigni A,
Brunelli C and Caraceni A: The role of paracetamol and nonsteroidal
anti-inflammatory drugs in addition to WHO Step III opioids in the
control of pain in advanced cancer. A systematic review of the
literature. Palliat Med. 26:305–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mbeunkui F and Johann DJ Jr: Cancer and
the tumor microenvironment: a review of an essential relationship.
Cancer Chemother Pharmacol. 63:571–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang CM and Yu J: Hypoxia-inducible
factor-1 as a therapeutic target in cancer. J Gastroenterol
Hepatol. 28:401–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zou Y, Guo CG and Zhang MM: Inhibition of
human hepatocellular carcinoma tumor angiogenesis by siRNA
silencing of VEGF via hepatic artery perfusion. Eur Rev Med
Pharmacol Sci. 19:4751–4761. 2015.PubMed/NCBI
|
|
11
|
Battello N, Zimmer AD, Goebel C, Dong X,
Behrmann I, Haan C, Hiller K and Wegner A: The role of HIF-1 in
oncostatin M-dependent metabolic reprogramming of hepatic cells.
Cancer Metab. 4:32016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang D, Li T, Li X, Zhang L, Sun L, He X,
Zhong X, Jia D, Song L, Semenza GL, et al: HIF-1-mediated
suppression of acyl-CoA dehydrogenases and fatty acid oxidation is
critical for cancer progression. Cell Rep. 8:1930–1942. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu Q, Liu L, Zhao Y, Zhang J, Wang D,
Chen J, He Y, Wu J, Zhang Z and Liu Z: Hypoxia induces genomic DNA
demethylation through the activation of HIF-1α and transcriptional
upregulation of MAT2A in hepatoma cells. Mol Cancer Ther.
10:1113–1123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen J, Ding Z, Peng Y, Pan F, Li J, Zou
L, Zhang Y and Liang H: HIF-1α inhibition reverses multidrug
resistance in colon cancer cells via downregulation of
MDR1/P-glycoprotein. PLoS One. 9:e988822014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu K, Babapoor-Farrokhran S, Rodrigues M,
Deshpande M, Puchner B, Kashiwabuchi F, Hassan SJ, Asnaghi L, Handa
JT, Merbs S, et al: Hypoxia-inducible factor 1 upregulation of both
VEGF and ANGPTL4 is required to promote the angiogenic phenotype in
uveal melanoma. Oncotarget. 7:7816–7828. 2016.PubMed/NCBI
|
|
16
|
Zhao C and Popel AS: Computational model
of microRNA control of HIF-VEGF pathway: insights into the
pathophysiology of ischemic vascular disease and cancer. PLOS
Comput Biol. 11:e10046122015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Masoud GN and Li W: HIF-1α pathway: Role,
regulation and intervention for cancer therapy. Acta Pharm Sin B.
5:378–389. 2015. View Article : Google Scholar : PubMed/NCBI
|
